A UPLC–MS/MS method for comparative pharmacokinetics study of morusin and morin in normal and diabetic rats

Biomedical Chromatography - Tập 33 Số 7 - 2019
Jia Liu1,2,3,4, Yanling Mu1, Shan Xiong1, Peilu Sun1, Zhipeng Deng1
1Institute of Materia Medica, Shandong Academy of Medical Sciences, Jinan, Shandong, China
2Key Laboratory for Biotech-Drugs Ministry of Health, Jinan, Shandong, China
3Key Laboratory for Rare & Uncommon Diseases of Shandong Province Jinan Shandong China
4School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences, Jinan, Shandong, China

Tóm tắt

Abstract

The aim of this study was to establish and validate a rapid, selective and reliable ultra‐performance liquid chromatography–tandem mass spectrometry (UPLC–MS/MS) for simultaneous quantitations of morin and morusin, and to investigate their pharmacokinetics difference between normal and diabetic rats after oral administration. Plasma samples were pretreated via protein precipitation with acetonitrile. Genkwanin was used as internal standard (IS). Analytes and IS were separated on a Thermo Hypersil Gold C18 column (50 × 4.6 mm, 3 μm) using gradient elution. The mobile phase consisted of acetonitrile and 0.1% formic acid in water at a flow rate of 0.5 mL/min. Mass spectrometry detection was carried out by means of negative electrospray ionization source and multipe‐reaction monitoring mode. The transitions of m/z 300.9 → 151.2 for morin, m/z 419.2 → 297.1 for morusin and m/z 283.1 → 268.2 for IS were chosen for quantification. Calibration curves were linear in the range of 1.01–504.2 ng/mL (r2 ≥ 0.99) for morin and 1.02–522.3 ng/mL (r2 ≥ 0.99) for morusin. The lower limit of quantification was 1.02 ng/mL for morin and 1.05 ng/mL for morusin. The extraction recovery was >85.1% for each analyte. No obvious matrix effect was observed under the present UPLC–MS/MS conditions during all of the bioanalysis. The stability study demonstrated that morin and morusin remained stable during the whole analytical procedure. The method was successfully applied to support the pharmacokinetic comparisons of morin and morusin between normal and diabetic rats.

Từ khóa


Tài liệu tham khảo

Almeida J. R., 2012, Medicinal plants and natural compounds from the genus Morus (Moraceae) with hypoglycemic activity: A review, Intech, 11, 189

Altrad B., 2015, Progesterone ameliorates diabetic nephropathy in streptozotocin‐induced diabetic rats, Diabetology & Metabolic Syndrome, 7, 1

10.2174/0929867323666160106150821

10.1016/j.diabres.2018.02.023

Committee of Pharmacopoeia of P.R. China, 2015, Pharmacopoeia of People's Republic of China, Part 1, 298

10.1002/bmc.4021

10.1002/bmc.2863

10.1016/j.lfs.2005.10.010

10.1002/bmc.2949

10.1210/jc.2007-1817

10.1038/srep27156

10.1016/j.intimp.2013.03.029

10.1016/j.foodchem.2017.11.084

10.1016/j.jpba.2018.02.062

10.3390/molecules191117763

10.1016/j.jep.2017.02.003

10.1016/j.jep.2011.08.021

Lim S., 2015, Morusin induces cell death through inactivating STAT3 signaling in prostate cancer cells, American Journal of Cancer Research, 5, 289

10.3390/molecules23010133

Ma D., 2012, Effects of flavonoids in Morus indica on blood lipids and glucose in hyperlipidemia‐diabetic rats, Chinese Herbal Medicines, 4, 314

Ma L., 2017, Mori cortex prevents kidney damage through inhibiting expression of inflammatory factors in the glomerulus in streptozocin‐induced diabetic rats, Iranian Journal of Basic Medical Sciences, 20, 715

10.1155/2018/1067853

10.1016/j.bbrc.2018.09.085

10.1016/j.jep.2005.03.013

US Food and Drug Administration(2018).Guidance for industry: Bioanalytical method validation. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research and Center for Veterinary Medicine.

10.1016/j.diabres.2011.10.029

Thông tin
Thông tin xuất bản

Biomedical Chromatography

Tập 33 Số 7

Thông tin tác giả